Yang WQ, Xue LL, Wang JL. Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights. World J Gastroenterol 2025; 31(26): 108814 [DOI: 10.3748/wjg.v31.i26.108814]
Corresponding Author of This Article
Jing-Lin Wang, PhD, Researcher, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. cw20120817@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing 210008, Jiangsu Province, China
Author contributions: Yang WQ was primarily responsible for drafting this letter; Xue LL provided valuable suggestions; Wang JL meticulously revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Lin Wang, PhD, Researcher, Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, No. 321 Zhongshan Road, Nanjing 210008, Jiangsu Province, China. cw20120817@163.com
Received: April 24, 2025 Revised: June 6, 2025 Accepted: June 26, 2025 Published online: July 14, 2025 Processing time: 78 Days and 20.2 Hours
Core Tip
Core Tip: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive disorder intricately linked to aging through shared pathological pathways. The core mechanism driving aging-aggravated MASLD involves vitamin D receptor (VDR) dysregulation, which amplifies hepatic lipotoxicity by disrupting lipid metabolism and inducing ferroptosis. Although metabolic reprogramming initially serves as an adaptive response to stress, its dysregulation in aging accelerates inflammation and fibrosis. However, precisely targeting the VDR–p53 axis to modulate mitochondrial function and ferroptotic susceptibility, while balancing metabolic adaptation and cell death, remains a critical therapeutic challenge for halting disease progression.
